Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Disease Progression 1

Interventions

pembrolizumab 117Carboplatin 47Nivolumab 46Paclitaxel 34Cyclophosphamide 34Cisplatin 33Gemcitabine 30atezolizumab 28Specimen Handling 26venetoclax 25Magnetic Resonance Spectroscopy 25Docetaxel 24fludarabine 23Pemetrexed 23Radiotherapy 22Biopsy 22Bevacizumab 22Ipilimumab 21Azacitidine 21Dexamethasone 19durvalumab 18Radiosurgery 18Fluorouracil 17Cetuximab 16Trastuzumab 15fludarabine phosphate 14Leucovorin 14Cytarabine 14tislelizumab 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interleukin 1 Receptor Antagonist Protein × 1 year × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡